Literature DB >> 24638245

[No addition benefit from coadministration of trastuzumab and anthracyclines].

M Wilhelm1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24638245     DOI： 10.1007/s00066-014-0558-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Trastuzumab-related cardiotoxicity among older patients with breast cancer.

Authors:  Mariana Chavez-MacGregor; Ning Zhang; Thomas A Buchholz; Yufeng Zhang; Jiangong Niu; Linda Elting; Benjamin D Smith; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

2.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Authors:  Aman U Buzdar; Nuhad K Ibrahim; Deborah Francis; Daniel J Booser; Eva S Thomas; Richard L Theriault; Lajos Pusztai; Marjorie C Green; Banu K Arun; Sharon H Giordano; Massimo Cristofanilli; Debra K Frye; Terry L Smith; Kelly K Hunt; Sonja E Singletary; Aysegul A Sahin; Michael S Ewer; Thomas A Buchholz; Donald Berry; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

3.  Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

Authors:  André Robidoux; Gong Tang; Priya Rastogi; Charles E Geyer; Catherine A Azar; James N Atkins; Louis Fehrenbacher; Harry D Bear; Louis Baez-Diaz; Shakir Sarwar; Richard G Margolese; William B Farrar; Adam M Brufsky; Henry R Shibata; Hanna Bandos; Soonmyung Paik; Joseph P Costantino; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  Lancet Oncol       Date:  2013-10-04       Impact factor: 41.316

4.  Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Authors:  Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; A Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary Unzeitig; Melanie Royce; Linda M McCall; Michael S Ewer; Kelly K Hunt
Journal:  Lancet Oncol       Date:  2013-11-13       Impact factor: 41.316

5.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.